Syneron Medical Ltd. (NASDAQ: ELOS), a global market leader in the aesthetic medical device marketplace, announced today that the PicoWay® picosecond laser received U.S. Food and Drug Administration (FDA) clearance for the treatment of pigmented lesions.
The PicoWay picosecond laser previously received FDA clearance for the removal of tattoos in November 2014 and was launched in the US late in the fourth quarter 2014.
PicoWay incorporates picosecond (one trillionth of a second) pulse duration to generate an ultra-short pulse. The high energy ultra-short picosecond laser pulse creates a strong photo-mechanical impact that optimizes fracturing of tattoo ink or pigmentation.
The innovative PicoWay technology is integrated into a proven, reliable Candela platform which offers high reliability, superior performance and low cost of ownership. PicoWay is a remarkably innovative dual wavelength picosecond laser from Syneron Candela.The expansion of PicoWay's FDA clearance to include pigmented lesions further enhances the utility of the system, allowing practitioners to offer this next-generation technology for more of their pigment-related procedures
Health Canada cleared the PicoWay picosecond laser for the treatment of pigmented lesions and tattoo removal. The launch of PicoWay in Canada will begin during the second quarter 2015, and launch of the product in the US and other international markets during the fourth quarter 2014. The company sells its products in Canada through its direct North American sales organization PicoWay is a dual wavelength device, with 532nm and 1064nm wavelengths, which utilizes proprietary PicoWay technology to generate picosecond pulses for the treatment of pigmented lesions and tattoos of all colors.
Subscribe to PharmaTutor News Alerts by Email >>
